AR020091A1 - Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y - Google Patents
Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, yInfo
- Publication number
- AR020091A1 AR020091A1 ARP990102948A ARP990102948A AR020091A1 AR 020091 A1 AR020091 A1 AR 020091A1 AR P990102948 A ARP990102948 A AR P990102948A AR P990102948 A ARP990102948 A AR P990102948A AR 020091 A1 AR020091 A1 AR 020091A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- vaccines
- vaccine
- ndv
- cdna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
ADNc de paramyxovirus aviar que contiene por lo menos una secuencia de ácido nucleico correspondiente al extremo terminal 5 del genoma del paramyxovirusaviar y que permite generar un minigenoma replicante de paramyxovirus aviar particularmente permite generar una copia infecciosa de paramyxovirus aviar,particularmente a partir de un ADNc de longitud total . Proceso para generar virus infeccioso de la Enfermedad de Newcastle (NDV) totalmente a partir de ADNcclonado de longitud total, y uso de vacunas y pruebas de diagnostico generadas con dicho proceso y derivadas del mismo. El proceso ofrece la posibilidad demodificar el genoma del NDV por medio de la modificacion genética y da lugar a la introduccion de mutaciones, delecciones y/o inserciones. Este proceso sepuede emplear para modificar la virulencia de NDV, generando así vacunas vivas atenuadas con propiedades mejoradas. Este proceso se puede usar para modificarla constitucion genética del NDV, permitiendo de esta manera la generacion de vacunas marcadoras vivas del NDV que se pueden distinguir serologicamente de lascepas de campo del NDV. Copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, método para distinguir animales no vacunados o animalesvacunados ykit de diagnostico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98202054A EP0974660A1 (en) | 1998-06-19 | 1998-06-19 | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
Publications (1)
Publication Number | Publication Date |
---|---|
AR020091A1 true AR020091A1 (es) | 2002-04-10 |
Family
ID=8233832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990102948A AR020091A1 (es) | 1998-06-19 | 1999-06-18 | Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y |
Country Status (28)
Country | Link |
---|---|
US (3) | US6719979B2 (es) |
EP (2) | EP0974660A1 (es) |
JP (3) | JP2002518012A (es) |
KR (1) | KR20010053000A (es) |
CN (2) | CN1314942A (es) |
AR (1) | AR020091A1 (es) |
AT (1) | ATE367442T1 (es) |
AU (1) | AU754844B2 (es) |
BR (1) | BR9911383A (es) |
CA (1) | CA2334165A1 (es) |
CZ (1) | CZ300760B6 (es) |
DE (1) | DE69936585T2 (es) |
DK (1) | DK1088077T3 (es) |
EA (1) | EA004796B1 (es) |
ES (1) | ES2291029T3 (es) |
HR (1) | HRP20010042B1 (es) |
HU (1) | HUP0102429A3 (es) |
ID (1) | ID27343A (es) |
IL (2) | IL140381A0 (es) |
NO (1) | NO329193B1 (es) |
NZ (1) | NZ508982A (es) |
PL (1) | PL197722B1 (es) |
PT (1) | PT1088077E (es) |
SI (1) | SI1088077T1 (es) |
TR (1) | TR200100350T2 (es) |
UA (1) | UA77146C2 (es) |
WO (1) | WO1999066045A1 (es) |
ZA (1) | ZA200100241B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
US6146642A (en) * | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
US10383936B2 (en) * | 1999-05-05 | 2019-08-20 | University Of Maryland, College Park | Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector |
AU4971500A (en) * | 1999-05-05 | 2000-11-21 | University Of Maryland | Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines |
EP1074614B1 (en) * | 1999-07-27 | 2004-07-07 | Akzo Nobel N.V. | A recombinant Newcastle disease virus for in ovo vaccination |
CA2312626A1 (en) | 1999-07-27 | 2001-01-27 | Akzo Nobel N.V. | A recombinant newcastle disease virus as an embryo vaccine |
DE60139319D1 (en) | 2000-06-23 | 2009-09-03 | Intervet Int Bv | Us |
PT1383795E (pt) | 2000-11-02 | 2007-04-30 | Intervet Int Bv | Mutante da nucleoproteína do vírus da doença de newcastle recombinante como vacina marcadora |
KR100437888B1 (ko) * | 2001-07-30 | 2004-07-03 | 주식회사 인트론바이오테크놀로지 | 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법 |
IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
US7615209B2 (en) | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
ATE307606T1 (de) * | 2001-10-04 | 2005-11-15 | Ct Voor Onderzoek In Diergenee | Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung |
US8709442B2 (en) * | 2002-02-21 | 2014-04-29 | Icahn School Of Medicine At Mount Sinai | Recombinant negative strand virus RNA expression systems and vaccines |
TW200502402A (en) * | 2002-12-06 | 2005-01-16 | Wyeth Corp | Escape mutants of newcastle disease virus as marker vaccines |
US20040268442A1 (en) * | 2003-05-05 | 2004-12-30 | Dow Agrosciences Llc | Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production |
NZ543348A (en) * | 2003-05-05 | 2008-08-29 | Thompson Boyce Plant Res | Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
ATE478137T1 (de) | 2003-06-20 | 2010-09-15 | Microbix Biosystems Inc | Verbesserungen bei der virusproduktion |
US7527638B2 (en) | 2003-12-16 | 2009-05-05 | Depuy Spine, Inc. | Methods and devices for minimally invasive spinal fixation element placement |
MY146476A (en) | 2004-06-24 | 2012-08-15 | Boehringer Ingelheim Vetmed | Method of diagnosing lawsonia intracellularis |
GB0423681D0 (en) * | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
NZ585895A (en) | 2004-11-12 | 2011-05-27 | Bayer Schering Pharma Ag | Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising a toxin |
US7871626B2 (en) | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
PL2251034T3 (pl) * | 2005-12-02 | 2018-07-31 | Icahn School Of Medicine At Mount Sinai | Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów |
AU2007224430A1 (en) * | 2006-03-15 | 2007-09-20 | Intervet International B.V. | Recombinant Newcastle disease virus expressing H5 hemagglutinin of avian influenza virus |
CA2638746C (en) * | 2006-03-15 | 2014-12-02 | Intervet International B.V. | Recombinant mononegaviral virus vectors |
KR100776398B1 (ko) * | 2006-03-23 | 2007-11-28 | 주식회사 고려비엔피 | 조류 hn 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스 |
KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
KR100874256B1 (ko) | 2007-02-12 | 2008-12-16 | 대한민국 | 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도 |
KR100955502B1 (ko) * | 2007-11-30 | 2010-04-30 | 대한민국 | 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도 |
EP2085092A1 (en) | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
US7794714B2 (en) * | 2008-03-14 | 2010-09-14 | The United States Of America As Represented By The Secretary Of Agriculture | Newcastle disease virus monoclonal antibodies |
US20090258035A1 (en) * | 2008-03-21 | 2009-10-15 | The United States Of America, As Represented By The Secretary Of Agriculture | Avian virus vaccines and uses thereof |
CN102281896A (zh) * | 2008-11-19 | 2011-12-14 | 阿维-梅克斯实验室公司 | 重组失活病毒载体疫苗 |
WO2010091262A1 (en) | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
CA2771540C (en) * | 2009-08-21 | 2019-01-15 | Merial Limited | Recombinant avian paramyxovirus vaccine and method for making and using thereof |
US20110110975A1 (en) * | 2009-11-06 | 2011-05-12 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
ATE539148T1 (de) | 2009-11-30 | 2012-01-15 | United Cancer Res Inst | Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs |
WO2012151391A2 (en) | 2011-05-04 | 2012-11-08 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
EP2797613B1 (en) | 2011-10-27 | 2019-12-04 | Wellstat Ophthalmics Corporation | Vectors encoding rod-derived cone viability factor |
ES2719409T5 (es) | 2011-11-30 | 2022-12-07 | Boehringer Ingelheim Animal Health Usa Inc | Vectores recombinantes de Gallid herpesvirus 3 (mdv serotipo 2) que expresan antígenos de patógenos aviares y usos de los mismos |
KR101374192B1 (ko) * | 2011-12-21 | 2014-03-14 | 대한민국 | 제4형 조류파라믹소바이러스 hn 단백질 및 이를 포함하는 hi법 검사용 항원진단액 |
BR112015021414B1 (pt) | 2013-03-14 | 2020-11-10 | Icahn School Of Medicine At Mount Sinai | vírus da doença newcastle e seus usos |
CN104059942B (zh) * | 2013-03-20 | 2016-12-28 | 湖北省农业科学院畜牧兽医研究所 | 新城疫病毒耐热活疫苗载体系统及其应用 |
US20140341950A1 (en) * | 2013-05-15 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Recombinant avian paramyxovirus vaccine and method for making and using thereof |
SG11201607130RA (en) | 2014-02-27 | 2016-09-29 | Viralytics Ltd | Combination method for treatment of cancer |
US10780158B2 (en) | 2015-11-16 | 2020-09-22 | Georgia State University Research Foundation, Inc. | Tunable vaccine platform against pathogens of the paramyxovirus family |
JP2019506168A (ja) | 2016-02-03 | 2019-03-07 | シージー ディスカバリー インコーポレイテッドCg Discovery, Inc. | 異種エピトープ及び/又は改変された成熟切断部位を有するインフルエンザヘマグルチニンの組成物 |
US10063211B2 (en) * | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
US10196616B2 (en) | 2017-02-15 | 2019-02-05 | The United States Of America, As Represented By The Secretary Of Agriculture | Altered avian virus for in-ovo inoculation and methods of use thereof |
MX2020008988A (es) * | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
CA3106170A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
CN109735552A (zh) * | 2019-02-27 | 2019-05-10 | 苏州世诺生物技术有限公司 | 禽新城疫病毒新型基因工程亚单位疫苗 |
CN110018304A (zh) * | 2019-05-15 | 2019-07-16 | 河南省农业科学院 | 一种新城疫抗体阻断检测试纸 |
CN110240635B (zh) * | 2019-06-10 | 2022-04-22 | 华中农业大学 | 检测新城疫病毒抗体的多肽及其elisa检测试剂盒 |
CN110257562A (zh) * | 2019-07-31 | 2019-09-20 | 河北农业大学 | 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用 |
KR102154796B1 (ko) * | 2019-10-18 | 2020-09-22 | 주식회사 바이오포아 | 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신 |
CN110938711A (zh) * | 2019-12-20 | 2020-03-31 | 河北农业大学 | 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法 |
CN111334528B (zh) * | 2020-03-20 | 2022-02-18 | 山东农业大学 | 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用 |
CN112048484A (zh) * | 2020-07-27 | 2020-12-08 | 华南农业大学 | 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗 |
CN114214338B (zh) * | 2021-08-26 | 2023-02-03 | 扬州大学 | 猪源piv5全长感染性克隆及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
ES2210273T5 (es) | 1994-07-18 | 2010-03-29 | Conzelmann, Karl-Klaus, Prof. Dr. | Virus con arn de cadena negativa no segmentado recombinante infeccioso. |
WO1996040880A1 (en) * | 1995-06-07 | 1996-12-19 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
DE69510207T3 (de) * | 1995-08-09 | 2007-02-15 | Schweiz. Serum- & Impfinstitut Bern | Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren |
EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
EP0974660A1 (en) | 1998-06-19 | 2000-01-26 | Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) | Newcastle disease virus infectious clones, vaccines and diagnostic assays |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
-
1998
- 1998-06-19 EP EP98202054A patent/EP0974660A1/en not_active Withdrawn
-
1999
- 1999-06-17 CA CA002334165A patent/CA2334165A1/en not_active Abandoned
- 1999-06-17 ES ES99926984T patent/ES2291029T3/es not_active Expired - Lifetime
- 1999-06-17 CN CN99809714A patent/CN1314942A/zh active Pending
- 1999-06-17 IL IL14038199A patent/IL140381A0/xx active IP Right Grant
- 1999-06-17 BR BR9911383-0A patent/BR9911383A/pt not_active IP Right Cessation
- 1999-06-17 CZ CZ20004707A patent/CZ300760B6/cs not_active IP Right Cessation
- 1999-06-17 TR TR2001/00350T patent/TR200100350T2/xx unknown
- 1999-06-17 JP JP2000554854A patent/JP2002518012A/ja not_active Withdrawn
- 1999-06-17 AU AU43991/99A patent/AU754844B2/en not_active Ceased
- 1999-06-17 HU HU0102429A patent/HUP0102429A3/hu unknown
- 1999-06-17 KR KR1020007014397A patent/KR20010053000A/ko not_active Application Discontinuation
- 1999-06-17 ID IDW20010146A patent/ID27343A/id unknown
- 1999-06-17 EA EA200100057A patent/EA004796B1/ru not_active IP Right Cessation
- 1999-06-17 PL PL348300A patent/PL197722B1/pl not_active IP Right Cessation
- 1999-06-17 WO PCT/NL1999/000377 patent/WO1999066045A1/en active IP Right Grant
- 1999-06-17 PT PT99926984T patent/PT1088077E/pt unknown
- 1999-06-17 CN CNA2008100921449A patent/CN101275142A/zh active Pending
- 1999-06-17 DE DE69936585T patent/DE69936585T2/de not_active Expired - Lifetime
- 1999-06-17 NZ NZ508982A patent/NZ508982A/en unknown
- 1999-06-17 AT AT99926984T patent/ATE367442T1/de active
- 1999-06-17 SI SI9930990T patent/SI1088077T1/sl unknown
- 1999-06-17 DK DK99926984T patent/DK1088077T3/da active
- 1999-06-17 UA UA2001010408A patent/UA77146C2/uk unknown
- 1999-06-17 EP EP99926984A patent/EP1088077B2/en not_active Expired - Lifetime
- 1999-06-18 AR ARP990102948A patent/AR020091A1/es not_active Application Discontinuation
-
2000
- 2000-12-15 NO NO20006406A patent/NO329193B1/no not_active IP Right Cessation
- 2000-12-18 IL IL140381A patent/IL140381A/en not_active IP Right Cessation
- 2000-12-19 US US09/741,744 patent/US6719979B2/en not_active Expired - Fee Related
-
2001
- 2001-01-09 ZA ZA2001/00241A patent/ZA200100241B/en unknown
- 2001-01-15 HR HR20010042A patent/HRP20010042B1/xx not_active IP Right Cessation
-
2004
- 2004-02-26 US US10/788,232 patent/US7332169B2/en not_active Expired - Fee Related
- 2004-04-15 US US10/824,782 patent/US7547442B2/en not_active Expired - Fee Related
-
2005
- 2005-12-01 JP JP2005347888A patent/JP2006141398A/ja active Pending
-
2009
- 2009-02-04 JP JP2009023349A patent/JP2009261387A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR020091A1 (es) | Adnc de paramyxovirus aviar (particularmente virus de la enfermedad de newcastle), arn, metodo para generar copias de virus infeccioso de paramyxovirusaviar, copia de virus infeccioso, vacuna que comprende dicho virus, vacuna viva, metodo para distinguir animales no vacunados o animales vacunados, y | |
AR008620A1 (es) | Vacuna viva recombinante, fragmento de adn y virus iltv que la componen | |
Matsuno et al. | A candidate for a new serotype of human rotavirus | |
Gohm et al. | Detection of Newcastle disease virus in organs and faeces of experimentally infected chickens using RT-PCR | |
CY1106493T1 (el) | Μεταλλαγμενη μορφη νουκλεοπρωτεϊνης ανασυνδυασμενου ιου ασθενειας του newcastle ως εμβολιο δεικτης | |
Gelb Jr et al. | Characterization of nephropathogenic infectious bronchitis virus DMV/1639/11 recovered from Delmarva broiler chickens in 2011 | |
Chen et al. | Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate | |
Zhao et al. | Efficacy of an inactivated bivalent vaccine against the prevalent strains of Newcastle disease and H9N2 avian influenza | |
MY163972A (en) | Attenuated recombinant newcastle disease virus and vaccine containing the same | |
Zou et al. | Efficient strategy for constructing duck enteritis virus-based live attenuated vaccine against homologous and heterologous H5N1 avian influenza virus and duck enteritis virus infection | |
Banner et al. | The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development | |
Zhou et al. | Establishment of reverse genetics system for infectious bronchitis virus attenuated vaccine strain H120 | |
Spackman et al. | The pathogenesis of turkey origin reoviruses in turkeys and chickens | |
Crispo et al. | Partial molecular characterization and pathogenicity study of an avian reovirus causing tenosynovitis in commercial broilers | |
Wang et al. | Changes in VP2 gene during the attenuation of very virulent infectious bursal disease virus strain Gx isolated in China | |
HUT52555A (en) | Process for production of virus and vaccina against recombinant marek-desease | |
Jackwood et al. | Pathogenicity of genome reassortant infectious bursal disease viruses in chickens and turkeys | |
BR0207988A (pt) | Cepas atenuadas vivas de vìrus de prrs | |
AR019250A1 (es) | Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje | |
Alvarado et al. | Evaluation of the protection conferred by commercial vaccines against the California 99 isolate of infectious bronchitis virus | |
El Khantour et al. | Protective efficacy evaluation of four inactivated commercial vaccines against low pathogenic avian influenza H9N2 virus under experimental conditions in broiler chickens | |
Egaña-Labrin et al. | Avian reoviruses of the same genotype induce different pathology in chickens | |
Kim et al. | Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus | |
Markis | Evaluation of pathogenicity and antigenicity of avian reoviruses and disease control through vaccination | |
Krell et al. | Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |